AbbVie (ABBV) Non-Current Debt (2012 - 2026)
AbbVie (ABBV) posted quarterly Non-Current Debt of $64.5 billion for Q1 2026, little changed year-over-year from $64.5 billion in Q1 2025, and up 9.49% quarter-over-quarter from $58.9 billion in Q4 2025.
AbbVie (ABBV) Non-Current Debt (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Non-Current Debt for 15 consecutive years, with $64.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt changed 0.01% year-over-year to $64.5 billion; the TTM figure through Mar 2026 stood at $64.5 billion (changed 0.01% YoY), while the FY2025 annual figure was $58.9 billion, down 2.32% from the prior year.
- Non-Current Debt grew to $64.5 billion in Q1 2026 per ABBV's latest filing, from $58.9 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $64.5 billion in Q1 2026 and bottomed at $52.2 billion in Q4 2023.
- Historically, Non-Current Debt has averaged $60.1 billion across 5 years, with a median of $60.3 billion in 2024.
- On a YoY basis, Non-Current Debt climbed as much as 5939.9% in 2022 and fell as far as 17.83% in 2022.
- AbbVie's Non-Current Debt stood at $59.1 billion in 2022, then fell by 11.74% to $52.2 billion in 2023, then advanced by 15.61% to $60.3 billion in 2024, then dropped by 2.32% to $58.9 billion in 2025, then gained by 9.49% to $64.5 billion in 2026.
- Business Quant data shows ABBV's Non-Current Debt at $64.5 billion in Q1 2026, $58.9 billion in Q4 2025, and $63.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.48 Bn |
| Mar 31, 2026 | 64.53 Bn |
| Dec 31, 2025 | 58.94 Bn |
| Sep 30, 2025 | 62.97 Bn |
| Jun 30, 2025 | 62.96 Bn |
| Mar 31, 2025 | 64.53 Bn |
| Dec 31, 2024 | 60.34 Bn |
| Sep 30, 2024 | 58.51 Bn |
| Jun 30, 2024 | 58.05 Bn |
| Mar 31, 2024 | 63.81 Bn |
| Dec 31, 2023 | 52.19 Bn |
| Sep 30, 2023 | 55.63 Bn |
| Jun 30, 2023 | 55.81 Bn |
| Mar 31, 2023 | 59.29 Bn |
| Dec 31, 2022 | 59.14 Bn |
| Sep 30, 2022 | 60.40 Bn |
| Jun 30, 2022 | 61.00 Bn |
| Mar 31, 2022 | 63.52 Bn |
| Dec 31, 2021 | 64.19 Bn |
| Sep 30, 2021 | 1.00 Bn |